Renal insufficiency after bone marrow transplantation in children.
Between 1975 and 1988, 92 pediatric patients have undergone bone marrow transplantation (BMT) at our institution for malignant or immune deficiency disease. We evaluated in a retrospective fashion 64 of these patients who survived beyond the first 60 days post-BMT. The clinical course was divided into: less than 60 days post-BMT (early) and greater than 60 days post-BMT (late). The presence or absence of renal insufficiency was noted as well as all known potential factors predisposing to insufficiency. Step-wise regression analysis was then performed to determine which of the factors were most significantly associated with renal dysfunction during the two periods. The follow-up period was 2 months to 11 years (mean 17.5 months). The mean age of the patients was 7.6 years (1 month-18 years). Fifty percent of the patients had renal insufficiency during the early period and 28% of the patients had insufficiency after the initial 60 days. Three major predictors of renal insufficiency were discovered. Cyclosporin A or amphotericin B early or late post-BMT was independently predictive of developing insufficiency during the same period. Conditioning with total body irradiation was a predictor for insufficiency in both periods. Early insufficiency was not predictive of late insufficiency. Hypertension was present in 31% of patients during the early period and in 16% during the late period. Hypertension was strongly associated with cyclosporin use and renal insufficiency. Renal insufficiency is a frequent sequela in children following BMT and likely results from a combination of radiation injury and drug toxicity.
Van Why
S K
SK
Department of Pediatrics, University of Wisconsin School of Medicine, Madison.
Friedman
A L
AL
Wei
L J
LJ
Hong
R
R
D000293:Adolescent; D000666:Amphotericin B / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003524:Cyclosporins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007223:Infant; D007674:Kidney Diseases / Q000139:chemically induced / Q000209:etiology*; D012044:Regression Analysis; D012189:Retrospective Studies
D003524:Cyclosporins; D000666:Amphotericin B